Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26483327 · 1 trial · 7 indications
| Name | Type | Description |
|---|---|---|
| JNJ-26483327 | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of solid malignancy that is advanced or refractory and progressing and for which standard treatments do not exist or are no longer effective * radiological assessment of disease within 4 weeks of first study drug administration * overall health status as de...
JNJ-26483327 is an investigational small molecule being developed for the treatment of advanced and/or refractory solid malignancies. It is a protein kinase inhibitor intended for oncology use. The drug was studied in a Phase 1 clinical trial to evaluate its safety and to determine the maximum tolerated dose in patients with advanced solid tumors.
JNJ-26483327 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is an investigational small molecule in the oncology therapeutic area, studied as a protein kinase inhibitor for patients with advanced and/or refractory solid malignancies.
JNJ-26483327 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A single Phase 1 trial has been completed, which was designed as a safety and dose-finding study in patients with advanced and/or refractory solid malignancies. The drug remains in early-stage clinical development.
JNJ-26483327 has been studied in one clinical trial, registered as NCT00676299. This was a Phase 1, open-label, uncontrolled study titled 'A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.' The trial enrolled 19 patients aged 18 years and older and has been completed.
JNJ-26483327 works as a protein kinase inhibitor. By inhibiting protein kinases, the drug is designed to interfere with signaling pathways that can drive cancer cell growth and survival. This mechanism is being investigated in the context of advanced and/or refractory solid malignancies, where the drug's safety and maximum tolerated dose were evaluated in a Phase 1 trial.